Xenalon
Brand names,
Xenalon
Analogs
Xenalon
Brand Names Mixture
Xenalon
Chemical_Formula
C33H30N4O2
Xenalon
RX_link
http://www.rxlist.com/cgi/generic2/telmisartan.htm
Xenalon
fda sheet
Xenalon
msds (material safety sheet)
Xenalon
Synthesis Reference
No information avaliable
Xenalon
Molecular Weight
514.617 g/mol
Xenalon
Melting Point
261-263oC
Xenalon
H2O Solubility
Practically insoluble
Xenalon
State
Solid
Xenalon
LogP
7.245
Xenalon
Dosage Forms
Tablets
Xenalon
Indication
For the treatment of hypertension.
Xenalon
Pharmacology
Telmisartan is an orally active nonpeptide angiotensin II antagonist that acts on the AT1 receptor subtype. New studies suggest that telmisartan may also have PPARγ agonistic properties that could potentially confer beneficial metabolic effects. This observation is currently being explored in clinical trials. Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan works by blocking the vasoconstrictor and aldosterone secretory effects of angiotensin II.
Xenalon
Absorption
Absolute bioavailability depends on dosage. Food slightly decreases the bioavailability (a decrease of about 6% is seen when the 40-mg dose is administered with food).
Xenalon
side effects and Toxicity
Intravenous LD50 in rats is 150-200 mg/kg in males and 200 to 250 mg/kg in females. Acute oral toxicity is low: no deaths and no changes occurred in rats or dogs at 2000 mg/kg, the highest dose tested. Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan would be hypotension, dizziness and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.
Xenalon
Patient Information
Xenalon
Organisms Affected
Humans and other mammals